Cover Image
市場調查報告書

角膜乾燥症 (乾眼症) :開發中產品分析

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 219724
出版日期 內容資訊 英文 192 Pages
訂單完成後即時交付
價格
Back to Top
角膜乾燥症 (乾眼症) :開發中產品分析 Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 192 Pages
簡介

乾眼症症候群同時也被稱之為乾性角結膜炎(KCS)或乾燥角膜炎,是淚液及眼睛表面的多因子疾病。由於眼睛表面的潛在性損傷造成不適感、視覺障礙、淚液層不穩定性。常見的症狀有眼睛疲勞、畏光刺眼、充血等。危險因子除了年齡之外,還有可能因雷射眼科手術、藥劑等因素所造成。

本報告提供角膜乾燥症 (乾眼症) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

角膜乾燥症 (乾眼症)的概要

治療藥的開發

  • 開發中產品的概要

角膜乾燥症 (乾眼症) :企業開發中的治療藥

角膜乾燥症 (乾眼症) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

角膜乾燥症 (乾眼症) :企業開發中的產品

角膜乾燥症 (乾眼症)的治療藥的開發企業

  • AB2 Bio Ltd.
  • Akari Therapeutics, Plc
  • Allergan Plc
  • Circadian Technologies Limited
  • Delenex Therapeutics AG
  • Digna Biotech, S.L.
  • Dompe Farmaceutici S.p.A.
  • HanAll Biopharma Co., Ltd.
  • Herantis Pharma Plc
  • Huons Co., Ltd.
  • InSite Vision Incorporated
  • Kala Pharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Kukje Pharmaceutical Industry Co., Ltd.
  • Laboratorios Sophia S.A. de C.V.
  • Lee's Pharmaceutical Holdings Limited
  • Lipicard Technologies Limited
  • Merck & Co., Inc.
  • Mimetogen Pharmaceuticals Inc.
  • Mitotech S.A.
  • Nanomerics Ltd
  • Neuroptis Biotech
  • Novaliq GmbH
  • Ocular Therapeutix, Inc.
  • Oculis ehf
  • OncoNOx ApS
  • 大塚集團
  • Parion Sciences, Inc.
  • PharmaReaserch Products Co., Ltd.
  • RegeneRx Biopharmaceuticals, Inc.
  • Rigel Pharmaceuticals, Inc.
  • Samjin Pharmaceutical Co., Ltd.
  • 參天製藥
  • 生化學工業
  • Shire Plc
  • Sucampo Pharmaceuticals, Inc.
  • TearSolutions, LLC.
  • Xigen SA

角膜乾燥症 (乾眼症) :治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

角膜乾燥症 (乾眼症) :最近的開發平台趨勢

角膜乾燥症 (乾眼症) :暫停中的計劃

角膜乾燥症 (乾眼症) :開發中止的產品

角膜乾燥症 (乾眼症) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8455IDB

Summary

Global Markets Direct's, 'Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016', provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)
  • The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects
  • The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Keratoconjunctivitis sicca (Dry Eye) Overview
  • Therapeutics Development
    • Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview
    • Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis
  • Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies
  • Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Investigation by Universities/Institutes
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies
  • Keratoconjunctivitis sicca (Dry Eye) - Products under Investigation by Universities/Institutes
  • Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development
    • AB2 Bio Ltd.
    • Allergan Plc
    • Ascendia Pharmaceuticals LLC
    • Chong Kun Dang Pharmaceutical Corp.
    • Digna Biotech, S.L.
    • Dompe Farmaceutici S.p.A.
    • HanAll Biopharma Co., Ltd.
    • Herantis Pharma Plc
    • Huons Co., Ltd.
    • InSite Vision Incorporated
    • Kala Pharmaceuticals, Inc.
    • Kissei Pharmaceutical Co., Ltd.
    • KPI Therapeutics, Inc.
    • Kukje Pharmaceutical Industry Co., Ltd.
    • Laboratoires Thea S.A.
    • Lee's Pharmaceutical Holdings Limited
    • Lipicard Technologies Limited
    • Merck & Co., Inc.
    • Mimetogen Pharmaceuticals Inc.
    • Mitotech S.A.
    • Nanomerics Ltd
    • Neuroptis Biotech
    • Novaliq GmbH
    • Ocular Therapeutix, Inc.
    • Oculis ehf
    • OncoNOx ApS
    • Otsuka Holdings Co., Ltd.
    • Parion Sciences, Inc.
    • Quorum Innovations LLC
    • RegeneRx Biopharmaceuticals, Inc.
    • Rigel Pharmaceuticals, Inc.
    • Samjin Pharmaceutical Co., Ltd.
    • Santen Pharmaceutical Co., Ltd.
    • Seikagaku Corporation
    • Sucampo Pharmaceuticals, Inc.
    • TearSolutions, LLC.
    • TopiVert Ltd
    • Xigen SA
  • Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AGN-223575 - Drug Profile
    • AGN-232411 - Drug Profile
    • Androgen Tears - Drug Profile
    • AVA-3486 - Drug Profile
    • AVX-012 - Drug Profile
    • BRM-421 - Drug Profile
    • cinhyaluronate sodium - Drug Profile
    • Cis-Urocanic Acid - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine SR - Drug Profile
    • dexamethasone acetate SR - Drug Profile
    • diclofenac sodium - Drug Profile
    • diquafosol tetrasodium - Drug Profile
    • disitertide - Drug Profile
    • Drugs to Agonize FPR2 for Dry Eye - Drug Profile
    • Elate Ocular - Drug Profile
    • HL-036 - Drug Profile
    • HU-007 - Drug Profile
    • hyaluronate sodium - Drug Profile
    • ISV-101 - Drug Profile
    • K-089 - Drug Profile
    • KeraKlear - Drug Profile
    • KJ-14003 - Drug Profile
    • KL-7016 - Drug Profile
    • KPI-190 - Drug Profile
    • Lacripep - Drug Profile
    • LME-636 - Drug Profile
    • loteprednol etabonate - Drug Profile
    • LT-4002 - Drug Profile
    • LT-4003 - Drug Profile
    • NOP-3 - Drug Profile
    • NOP-5 - Drug Profile
    • Nov-03 - Drug Profile
    • OC-301 - Drug Profile
    • OX-1001 - Drug Profile
    • ozagrel - Drug Profile
    • P-321 - Drug Profile
    • plastoquinone decyl triphenylphosphonium bromide - Drug Profile
    • PPL-003 - Drug Profile
    • Qi-204 - Drug Profile
    • R-348 - Drug Profile
    • rebamipide - Drug Profile
    • Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile
    • RGN-259 - Drug Profile
    • RP-101 - Drug Profile
    • RU-101 - Drug Profile
    • SA-001 - Drug Profile
    • SJP-002 - Drug Profile
    • Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye - Drug Profile
    • ST-266 - Drug Profile
    • tadekinig alfa - Drug Profile
    • tavilermide hydrochloride - Drug Profile
    • TOP-1630 - Drug Profile
    • XG-104 - Drug Profile
    • ZK-003 - Drug Profile
    • zucapsaicin - Drug Profile
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects
  • Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products
  • Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016
  • Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by AB2 Bio Ltd., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea S.A., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech S.A., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co., Ltd., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions, LLC., H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..1), H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..2), H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..3), H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..4), H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..5), H2 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016
  • Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top